Viking Therapeutics Inc. (VKTX)
NASDAQ: VKTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VKTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.16B
- EPS (TTM)
- -$5.42
- Dividend yield
- None
- 52-week range
- 23.82 – 43.10
- Day range
- 24.67 – 26.50
- Volume / Avg
- 3.65M / 5.31M
- Beta
- —
- Shares outstanding
- 127.52M
52-week range
VKTX stock today
Shares of Viking Therapeutics (VKTX) finished lower on Nov 20 at $24.77, a drop of 4.14% or $1.07 per share, versus the S&P 500's 3.70% decline. Shares are 42.5% below their 52-week high of $43.10, set on Sep 23, 2026 and 4.0% above the 52-week low of $23.82, near the bottom of the past year's range. VKTX is down 29.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 27.7%.
Viking Therapeutics has posted a net loss over the last twelve months (EPS of -$5.42), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Viking Therapeutics
Company profileViking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Brian Lian Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 74
- IPO year
- 2015
- Website
- vikingtherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, Viking Therapeutics generated $0 in revenue, up 0.0% from fiscal 2024. Viking Therapeutics reported a net loss of $359.6 million, compared with a loss of $110.0 million a year earlier. Diluted earnings per share came in at -$3.19.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Growth | — | — | — | — | — |
| Net income | $-359.64M | $-109.96M | $-85.89M | $-68.87M | $-54.99M |
| EPS (diluted) | $-3.19 | $-1.01 | $-0.91 | $-0.90 | $-0.71 |
Analyst forecast
ForecastConsensus (21 analysts)
strong_buy
Avg. price target
$95.32+284.82%
- Strong buy 5
- Buy 14
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 28, 2026
- EPS actual vs est.
- $-0.81 vs $1.00
- Surprise
- -181.00%
VKTX news
All VKTX news- Have $1,000? This Beaten-Down Biotech Has 4 Phase 3 Obesity Trials Underway.Nasdaq
- Viking: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Viking Shares New VK2735 Data, Reports BMI And Metabolic Improvements After 13 WeeksNasdaqVKTX, BRK.A
- Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026PR Newswire
- 4 Key Stocks to Watch Across Diabetes and Obesity This Awareness DayNasdaqNVO, LLY, VKTX, GPCR
- Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028NasdaqVKTX, NVO, LLY, LEN.B
- Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?NasdaqLLY, VKTX
- Will Wegovy Pill Drive Renewed GLP-1 Growth Momentum for Novo Stock?NasdaqNVO, LLY, VKTX, GPCR
Viking Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ABCLAbCellera Biologics Inc. | 9.69 | -7.45% | $3.16B | vs VKTX |
| XERSXeris Biopharma Holdings Inc. | 16.97 | +2.11% | $3.10B | vs VKTX |
| BHCBausch Health Companies Inc. | 8.22 | -3.97% | $3.08B | vs VKTX |
| ARQTArcutis Biotherapeutics Inc. | 26.36 | -2.98% | $3.33B | vs VKTX |
| AMLXAmylyx Pharmaceuticals Inc. | 26.02 | -0.69% | $3.35B | vs VKTX |
| LEGNLegend Biotech Corporation ADR | 15.25 | -5.28% | $2.96B | vs VKTX |
| ACADACADIA Pharmaceuticals Inc. | 17.11 | -2.73% | $2.96B | vs VKTX |
| VRDNViridian Therapeutics Inc. | 29.96 | -4.71% | $3.40B | vs VKTX |
Indexes, lists and sector
Viking Therapeutics stock FAQ
What is Viking Therapeutics's stock price today?
VKTX last traded at $24.77 as of Nov 20, 4:00 PM EST, down 4.14% on the day. Prices are delayed at least 15 minutes.
Who is Viking Therapeutics's CEO?
Dr. Brian Lian Ph.D. is the chief executive officer of Viking Therapeutics Inc., which has about 74 employees.
What is the VKTX 52-week high?
The 52-week high for VKTX is $43.10 and the 52-week low is $23.82. The stock is currently 42.5% below its high.